 Home > Active Ingredient News > Digestive System Information > An article to understand HER2-targeted therapy for colorectal cancer

An article to understand HER2-targeted therapy for colorectal cancer

 Last Update: 2022-08-12
 Source: Internet
 Author: User

Tags

microvascular disease treatment

gram staining results

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

The distribution and prognostic role of HER2 in colorectal cancer

Distribution and prognostic role of HER2 in colorectal cancer

Metastatic colorectal cancer (mCRC) has a poor prognosis, with a 5-year survival rate of less than 20%, and is the second most common cause of cancer death worldwi.

Breast cancer and gastric cancer 10% to 15%

HER2 is a transmembrane receptor in the epidermal growth factor receptor (EGFR) fami.

HER2 amplification occurs in 5% of patients with RAS/BRAF wild-type mCRC and has also been reported in patients with KRAS tumor mutatio.

Although retrospective studies have shown that HER2 amplification is associated with resistance to anti-EGFR therapy, HER2 status has little effect on the prognosis of mCRC patients ^[1]

^[1]Guide

Since HER2 has been recognized as a therapeutic target for mCRC patients, there are currently standardized criteria for detecting HER2 amplification by immunohistochemistry (IHC) or in situ hybridization (ISH.

Immunity ^[2]

HER2-targeted therapy has strong potential

Many single-arm phase 2 studies of trastuzumab combination therapy have demonstrated that HER2 amplification is a true molecular target in patients with mCRC ^[3-7]

^[3-7]^[3]^[4]^[5]

The 2020 edition of the CSCO colorectal cancer diagnosis and treatment guidelines ^[8] added the recommendation of anti-HER2 therapy for the first time in the third-line or later-line treatment of colorectal canc.

diagnosis and treatment ^[8]

Summarize

Colorectal cancer is one of the important tumor diseases that affects the health of Chinese residen.

precise

references:

Yonesaka K, Zejnullahu K, Okamoto I, et .

Valtorta E, Martino C, Sartore-Bianchi A, et .

Tosi F, Sartore-Bianchi A, Lonardi S, et .

Strickler JH, Zemla T, Ou FS, et .

Meric-Bernstam F, Hurwitz H, Raghav KPS, et .

Gupta R, Garrett-Mayer E, Halabi S, et .

Nakamura Y, Okamoto W, Kato T, et .

Chinese Society of Clinical Oncology (CSCO) Colorectal Cancer Diagnosis and Treatment Guidelines 202Leave a message here

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

SEMAGLUTIDE GMP grade

CAS No.: 910463-68-2

Pharmacy Grade

$270.00/G FOB

Glycerol CAS NO.56-81-5 Glycerin, anhydrous 99% High Quality liquid

CAS No.: 56-81-5

Industrial grade

$1-1.2/KG FOB

Diosmectite

CAS No.: 1318-93-0

Pharmaceutical Grade

$9-11/KG FOB

Hot Tags

jobs united states(236)

united states jobs(223)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.